Humberto Lara-Guerra

Medical University of South Carolina

H指数:13

被引数:1,047

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy

Pembrolizumab联合或不维持Olaparib用于转移性鳞状NSCLC，对一线Pembrolizumab加化疗有反应

JOURNAL OF THORACIC ONCOLOGY

IF20.8

2025-02-011

OAAI

Phase III study of pembrolizumab plus MK-1084 vs pembrolizumab plus placebo as first-line treatment for metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 tumour proportion score (TPS) ≥50%: MK-1084-004

III期研究：评估pembrolizumab联合MK-1084与pembrolizumab联合安慰剂作为KRAS G12C突变且PD-L1肿瘤比例评分（TPS）≥50%的转移性非小细胞肺癌（NSCLC）一线治疗的疗效，研究编号MK-1084-004。

ANNALS OF ONCOLOGY

IF65.4

2024-09-012

PRE

Results from phase 3 KEYLYNK-008: Pembrolizumab (pembro) with and without maintenance olaparib (ola) after first-line (1L) pembro plus chemotherapy (chemo) for metastatic squamous non-small-cell lung cancer (sqNSCLC)

CANCER RESEARCH

IF16.6

2024-04-051

PRE

Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC)

CANCER RESEARCH

IF16.6

2024-04-050

PRE

KEYNOTE-B99: Phase II study of pembrolizumab plus investigational agents combined with chemotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC)

ANNALS OF ONCOLOGY

IF65.4

2021-12-012

Phase III study of pembrolizumab (Pembro) with concurrent chemoradiation therapy (CCRT) followed by pembro with or without olaparib (Ola) vs CCRT followed by durvalumab (Durva) in unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYLYNK-012

ANNALS OF ONCOLOGY

IF65.4

2020-09-015

OAAI

Randomized, placebo-controlled phase III study of 1L pembrolizumab (Pembro) plus carboplatin/taxane followed by pembro with or without maintenance olaparib in patients (Pts) with metastatic squamous non-small cell lung cancer (sqNSCLC): KEYLYNK-008

ANNALS OF ONCOLOGY

IF65.4

2020-09-014

PREAI

Phase I dose escalation trial of pegzilarginase in patients with advanced solid tumors

CANCER RESEARCH

IF16.6

2018-07-013

PRE

Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol

ANNALS OF ONCOLOGY

IF65.4

2016-05-01144

OAAI

The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform

DRUG DISCOVERY TODAY

IF7.5

2015-12-0163

OAAI

Using Ontology Fingerprints to disambiguate gene name entities in the biomedical literature

DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION

IF3.6

2015-04-0811

OAAI

Synergistic antitumor activity of AKT inhibitor MK2206 and FUS1-nanoparticles in LKB1 mutant NSCLC

CANCER RESEARCH

IF16.6

2012-04-010

PRE

The Role of Intrapulmonary De Novo Lymphoid Tissue in Obliterative Bronchiolitis after Lung Transplantation

JOURNAL OF IMMUNOLOGY

IF3.4

2009-06-0168

OAAI

MMP-Dependent Migration of Extrapulmonary Myofibroblast Progenitors Contributing to Posttransplant Airway Fibrosis in the Lung

AMERICAN JOURNAL OF TRANSPLANTATION

IF8.2

2009-05-0131

Comparison of computer-assisted instruction (CAI) versus traditional textbook methods for training in abdominal examination (Japanese experience)

MEDICAL EDUCATION

IF5.2

2004-10-0154

PREAI

Peripheral lung nodules - Fluoroscopically guided video-assisted thoracoscopic resection after computed tomogrophy-guided localizotion using platinum microcoils

ANNALS OF SURGERY

IF6.4

2004-09-01139

OAAI

Humberto Lara-Guerra

个人简介

教育背景

工作经历

荣誉奖项

研究方向